Show simple item record

dc.creatorSauvat, Allan
dc.creatorCiccosanti, Fabiola
dc.creatorColavita, Francesca
dc.creatorDi Rienzo, Martina
dc.creatorCastilletti, Concetta
dc.creatorCapobianchi, Maria Rosaria
dc.creatorKepp, Oliver
dc.creatorZitvogel, Laurence
dc.creatorFimia, Gian Maria
dc.creatorPiacentini, Mauro
dc.creatorKroemer, Guido
dc.date.accessioned2020-09-18T16:06:56Z
dc.date.available2020-09-18T16:06:56Z
dc.date.created2020-08-19
dc.identifier.issn2041-4889spa
dc.identifier.otherhttps://www.nature.com/articles/s41419-020-02842-xspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13457
dc.format.extent11 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCell Death & Diseasespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectmedicamentos que inhiben la replicación del SARS-CoV-2spa
dc.subjectepidemic of coronavirus diseasespa
dc.subjectinhibitors of viralspa
dc.titleOn-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1038/s41419-020-02842-xspa
dc.description.abstractenglishThe current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development of inhibitors of viral replication. Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor. We identified a cluster of SARS-CoV-2 antivirals with characteristics of lysosomotropic agents, meaning that they are lipophilic weak bases capable of penetrating into cells. These agents include cepharentine, chloroquine, chlorpromazine, clemastine, cloperastine, emetine, hydroxychloroquine, haloperidol, ML240, PB28, ponatinib, siramesine, and zotatifin (eFT226) all of which are likely to inhibit SARS-CoV-2 replication by non-specific (off-target) effects, meaning that they probably do not act on their ‘official’ pharmacological targets, but rather interfere with viral replication through non-specific effects on acidophilic organelles including autophagosomes, endosomes, and lysosomes. Imatinib mesylate did not fall into this cluster. In conclusion, we propose a tentative classification of SARS-CoV-2 antivirals into specific (on-target) versus non-specific (off-target) agents based on their physicochemical characteristics.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record